The earnings call highlighted strong progress in product development with promising Phase 2 data for NDV-01 and sepranolone, as well as a disciplined financial approach. However, there are concerns about increased cash usage and a decreased cash position.

Company Guidance -

Q3 2025

During the Relmada Therapeutics First Quarter 2025 Earnings Call, the company provided guidance for its two primary product candidates, NDV-01 and sepranolone. NDV-01, a novel bladder cancer treatment, demonstrated promising Phase 2 data with an 85% overall response rate at three months and 100% disease-free status in seven evaluable patients at six months. The company highlighted NDV-01's potential to improve non-muscle invasive bladder cancer care due to its sustained-release formulation and impressive safety profile, with no treatment-related adverse events greater than Grade 1. Meanwhile, sepranolone, aimed at treating Prader-Willi syndrome and Tourette syndrome, showed a competitive 28% peak reduction in the primary clinical endpoint in Phase 2 trials. With a cash balance of $27 million and a clean balance sheet, Relmada is focused on advancing these programs through key clinical and regulatory milestones in 2025 and beyond.

Addition of Promising Product Candidates

Relmada added two unique product candidates, NDV-01 for bladder cancer and sepranolone for Prader-Willi syndrome and Tourette syndrome, both with very encouraging Phase 2 data.

Positive Phase 2 Data for NDV-01

Initial proof-of-concept Phase 2 data for NDV-01 showed an overall response rate of 90% and a complete response in carcinoma in situ patients at 100%.

Strong Safety Profile for NDV-01

NDV-01 was well tolerated with no treatment-related adverse events greater than Grade 1.

Financial Position and Cost Management

Relmada has a $27.1 million cash balance and reported a decrease in net loss from $21.8 million in Q1 2024 to $17.6 million in Q1 2025.

Sepranolone's Potential in Treating Neurobehavioral Disorders

Sepranolone, with a broad safety database and promising Phase 2 results in Tourette syndrome, is expected to address sizeable underserved markets including Prader-Willi syndrome.

Relmada Therapeutics (RLMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RLMD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.45 / -	-0.72	―	―	―
Aug 07, 2025	2025 (Q2)	-0.46 / -0.30	-0.59	49.15% (+0.29)	―
May 12, 2025	2025 (Q1)	-0.48 / -0.58	-0.72	19.44% (+0.14)	―
Mar 27, 2025	2024 (Q4)	-0.67 / -0.62	-0.84	26.19% (+0.22)	―
Nov 07, 2024	2024 (Q3)	-0.68 / -0.72	-0.73	1.37% (+0.01)	―
Aug 07, 2024	2024 (Q2)	-0.83 / -0.59	-0.84	29.76% (+0.25)	―
May 08, 2024	2024 (Q1)	-0.85 / -0.72	-0.87	17.24% (+0.15)	―
Mar 19, 2024	2023 (Q4)	-0.83 / -0.84	-1.28	34.38% (+0.44)	―
Nov 08, 2023	2023 (Q3)	-0.91 / -0.73	-1.31	44.27% (+0.58)	―
Aug 08, 2023	2023 (Q2)	-0.90 / -0.84	-1.33	36.84% (+0.49)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RLMD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$0.60	―	―
May 12, 2025	$0.40	$0.39	-2.50%
Mar 27, 2025	$0.30	$0.30	0.00%
Nov 07, 2024	$3.26	$3.28	+0.61%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Relmada Therapeutics (RLMD) report earnings?

Relmada Therapeutics (RLMD) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Relmada Therapeutics (RLMD) earnings time?

Relmada Therapeutics (RLMD) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RLMD EPS forecast?

RLMD EPS forecast for the fiscal quarter 2025 (Q3) is -0.45.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing